EUVIMEDEUVIMED entdecken
Crossref

Salvage high-dose-rate brachytherapy for isolated seminal vesicle recurrence following definitive treatment for prostate cancer

Amani Chowdhury, Tracy Lim Yew Fai, Thitiwan Prachanukul, Gerry Lowe, George Kirby, Mohammed Abdul-Latif, Ami Mehta, Gillian Marks, Peter Ostler, Milan Anjanappa, Hannah Tharmalingam, Robert Hughes und 2 weitere

Brachytherapy · 2026

DOI: 10.1016/j.brachy.2026.08.003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brachytherapy, 2026. Verfasst von Amani Chowdhury und 13 weiteren Autor:innen. Beteiligte Einrichtung: Mount Vernon Cancer Centre, Northwood, UK. Electronic address: amani.chowdhury@nhs.net. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Brachytherapy, Salvage Therapy, Seminal Vesicles. Die Arbeit nennt 14 Literaturangaben. Gefördert von: Marie Curie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Isolated seminal vesicle recurrence following definitive treatment for prostate cancer is uncommon and optimal management remains unclear. This study reports outcomes following salvage high-dose-rate (HDR) brachytherapy for isolated seminal vesicle relapse. METHODS AND MATERIALS: A retrospective analysis was conducted between January 2016 and August 2025 at the Mount Vernon Cancer Centre, Northwood, United Kingdom. Seminal vesicle recurrence was identified using multiparametric MRI (mpMRI) or Positron Emission Tomography (PET) imaging; nine patients also underwent biopsy confirmation. Interstitial HDR brachytherapy was delivered at 19 Gy in a single fraction or 26 Gy in two fractions. Outcomes included relapse-free survival (RFS), freedom from next treatment (FFNT), metastasis-free survival (MFS), overall survival (OS), and treatment-related toxicity. RESULTS: Twenty-two patients were treated with salvage HDR brachytherapy. Recurrence was confirmed radiologically in all patients; 82% of patients were staged using prostate-specific membrane antigen or Choline PET. Median follow-up was 68.3 months (range 4.7-116.2). RFS was 71.3% at 2 years and 40.5% at 2 and 5 years, respectively; 12 relapses (54.5%) occurred. Median time to subsequent therapy was 62.5 months (95% CI: 46.8-71.9 months). MFS was 89.7%, 83.7%, and 75.4% at 1, 3, and 5 years. OS was 95% at 1 and 3 years and 88% at 5 years. Five deaths occurred during follow-up. Four patients (18%) developed late grade ≥3 toxicity, including two grade 4 events. CONCLUSIONS: Salvage HDR brachytherapy for isolated seminal vesicle recurrence provides meaningful disease control and may delay systemic therapy in selected patients, though toxicity risks require careful discussion. Longer interval between primary treatment and disease relapse, and a post-salvage PSA nadir of

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsBrachytherapySalvage TherapySeminal VesiclesNeoplasm Recurrence, LocalHumansMaleRetrospective StudiesAgedMiddle AgedRadiotherapy DosageAged, 80 and over

Stichwörter der Autor:innen

High-dose-rate brachytherapyProstate cancerRadio-recurrent prostate cancerSalvage brachytherapySeminal vesicle recurrence

Autor:innen und Institutionen

  • Mount Vernon Cancer Centre, Northwood, UK. Electronic address: amani.chowdhury@nhs.net.
  • Mount Vernon Cancer Centre, Northwood, UK.
  • Mount Vernon Cancer Centre, Northwood, UK; Division of Cancer Sciences, University of Manchester, Manchester, UK.

Förderung

  • Marie Curie

Zitieren

APA

Chowdhury, A., Fai, T. L. Y., Prachanukul, T., Lowe, G., Kirby, G., Abdul-Latif, M., Mehta, A., Marks, G., Ostler, P., Anjanappa, M., Tharmalingam, H., Hughes, R., Alonzi, R., & Hoskin, P. J. (2026). Salvage high-dose-rate brachytherapy for isolated seminal vesicle recurrence following definitive treatment for prostate cancer. Brachytherapy. https://doi.org/10.1016/j.brachy.2026.08.003

Vancouver

Chowdhury A, Fai TLY, Prachanukul T, Lowe G, Kirby G, Abdul-Latif M, et al. Salvage high-dose-rate brachytherapy for isolated seminal vesicle recurrence following definitive treatment for prostate cancer. Brachytherapy. 2026. doi:10.1016/j.brachy.2026.08.003

BibTeX
@article{Chowdhury2026,
  author = {Chowdhury, Amani and Fai, Tracy Lim Yew and Prachanukul, Thitiwan and Lowe, Gerry and Kirby, George and Abdul-Latif, Mohammed and Mehta, Ami and Marks, Gillian and Ostler, Peter and Anjanappa, Milan and Tharmalingam, Hannah and Hughes, Robert and Alonzi, Roberto and Hoskin, Peter J},
  title = {Salvage high-dose-rate brachytherapy for isolated seminal vesicle recurrence following definitive treatment for prostate cancer},
  journal = {Brachytherapy},
  year = {2026},
  doi = {10.1016/j.brachy.2026.08.003}
}
Kostenlos starten →